业绩总览 - 华尔街分析师预计公司季度每股收益为2.87美元，同比增长6.7% [1] - 预计季度营收为107.7亿美元，同比增长5.2% [1] - 过去30天内，共识每股收益预期被下调0.1% [1] 关键业务部门营收预期 - QTL（技术许可）部门营收预计为14亿美元，同比下降7.9% [4] - QCT（芯片业务）部门总营收预计为92.8亿美元，同比增长6.9% [5] - QCT-汽车业务营收预计为10.2亿美元，同比增长13.8% [4] - QCT-物联网业务营收预计为17亿美元，同比增长0.8% [4] - QCT-手机业务营收预计为65.6亿美元，同比增长7.6% [5] - 许可业务营收预计为15亿美元，同比下降12.4% [5] - 设备与服务营收预计为91.6亿美元，同比增长7.3% [6] 关键业务部门税前利润预期 - QTL部门税前利润预计为9.756亿美元，去年同期为11.2亿美元 [6] - QCT部门税前利润预计为26.6亿美元，去年同期为24.7亿美元 [7] 市场表现与预期 - 公司股价在过去一个月上涨5%，同期标普500指数上涨2.1% [7] - 公司Zacks排名为3（持有），预计短期内表现将与整体市场一致 [7]

Analysts on Wall Street project that Cava Group (CAVA) will announce quarterly earnings of $0.13 per share in its forthcoming report, representing a decline of 13.3% year over year. Revenues are projected to reach $293.31 million, increasing 20.3% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 18% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimate ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $5.00 per share in its forthcoming report, representing a decline of 10.4% year over year. Revenues are projected to reach $8.94 billion, increasing 5.2% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prio ...

Farmland Partners (FPI) came out with quarterly funds from operations (FFO) of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to FFO of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of +16.67%. A quarter ago, it was expected that this real estate investment trust specializing in farmland would post FFO of $0.04 per share when it actually produced FFO of $0.03, delivering a surprise of - ...

Wall Street analysts forecast that Rocket Companies (RKT) will report quarterly earnings of $0.04 per share in its upcoming release, pointing to a year-over-year decline of 50%. It is anticipated that revenues will amount to $1.75 billion, exhibiting an increase of 32.1% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 37.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their init ...

Analysts on Wall Street project that Insmed (INSM) will announce quarterly loss of -$1.32 per share in its forthcoming report, representing a decline of 3.9% year over year. Revenues are projected to reach $114.65 million, increasing 22.7% from the same quarter last year.The current level reflects a downward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over t ...

The upcoming report from Vulcan Materials (VMC) is expected to reveal quarterly earnings of $2.68 per share, indicating an increase of 20.7% compared to the year-ago period. Analysts forecast revenues of $2.25 billion, representing an increase of 12.5% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 3.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during thi ...

In its upcoming report, Crocs (CROX) is predicted by Wall Street analysts to post quarterly earnings of $2.37 per share, reflecting a decline of 34.2% compared to the same period last year. Revenues are forecasted to be $965.11 million, representing a year-over-year decrease of 9.1%.The consensus EPS estimate for the quarter has been revised 5.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during th ...

股价表现与分析师目标价 - 波士顿科学公司股价在过去四周上涨3%至101.11美元 [1] - 华尔街分析师给出的平均目标价为127美元 意味着潜在上涨空间达25.6% [1] - 31份短期目标价范围从113美元到140美元 最低和最高涨幅分别为11.8%和38.5% [2] - 目标价的标准差为6.38美元 较小的标准差表明分析师间共识度较高 [2][9] 分析师目标价的可靠性分析 - 分析师设定目标价的能力和公正性长期受到质疑 仅凭此做投资决策可能适得其反 [3] - 研究表明目标价经常误导投资者 很少能准确预示股价实际走向 [7] - 分析师可能因公司与所在机构存在业务关系而设定过于乐观的目标价 [8] - 投资者不应完全忽略目标价 但应保持高度怀疑态度 不应仅凭此做决策 [10] 盈利预期修正与投资前景 - 分析师对该公司盈利前景日益乐观 盈利预期上调形成强烈共识 [4][11] - 盈利预期修正的趋势被证明能有效预测股价上涨 [4][11] - 过去30天内 本年度Zacks共识盈利预期上调2% 有10次上调且无下调 [12] - 该公司目前获得Zacks Rank 2（买入）评级 位列覆盖股票的前20% 显示短期上涨潜力 [13] 综合投资观点 - 尽管共识目标价本身可能不可靠 但其暗示的股价方向是良好参考 [14] - 目标价的高度集中（低标准差）可作为深入研究公司基本面驱动力的起点 [9]

整体财务预期 - 华尔街分析师预计礼来公司季度每股收益为6.02美元，同比增长410.2% [1] - 预计季度营收为16.01亿美元，较去年同期增长40% [1] - 过去30天内，市场对季度每股收益的一致预期上调了0.3% [1] 关键产品销售额预期 - 预计Cyramza总净销售额为2.3779亿美元，同比增长0.8% [4] - 预计Humulin净销售额为1.8073亿美元，同比下降12.7% [4] - 预计Humalog净销售额为5.1259亿美元，同比下降4.1% [4] - 预计Forteo净销售额为9663万美元，同比下降18.2% [5] 分地区产品销售额预期 - 预计Cyramza美国区净销售额为1.0796亿美元，同比增长1.4% [5] - 预计Humalog国际净销售额为2.1255亿美元，同比增长0.8% [5] - 预计Humulin美国区净销售额为1.2625亿美元，同比下降15.8% [6] - 预计Humalog美国区净销售额为3.0004亿美元，同比下降7.4% [6] - 预计Forteo国际净销售额为4097万美元，同比下降11.7% [6] - 预计Forteo美国区净销售额为5566万美元，同比下降22.4% [7] 地理区域营收预期 - 预计美国地区总营收为111.3亿美元，同比增长42.5% [7] - 预计糖尿病药物Mounjaro在美国以外地区的净销售额为19.9亿美元，同比增长173.9% [7] 近期市场表现 - 过去一个月，礼来公司股价回报率为+13.9%，同期标普500指数回报率为+2.5% [8]